达雷妥尤单抗联合来那度胺和地塞米松治疗不适合移植的新诊断多发性骨髓瘤:MAIA研究的衰弱亚组分析
MAIA研究是一项3期试验,针对不适合移植的新诊断多发性骨髓瘤(NDMM)患者,比较达雷妥尤单抗联合来那度胺/地塞米松(D-Rd)与来那度胺/地塞米松(Rd)的疗效。本文按衰弱状态进行亚组分析,衰弱评估回顾性使用年龄、Charlson合并症指数和基线ECOG体能状态评分。中位随访36.4个月,非衰弱和衰弱亚组中D-Rd相比Rd均维持PFS获益,支持D-Rd的临床获益不受衰弱状态影响。
要点
- 非衰弱患者D-Rd组中位PFS未达到,Rd组41.7个月(HR 0.48,P<0.0001)。
- 衰弱患者D-Rd组中位PFS未达到,Rd组30.4个月(HR 0.62,P=0.003)。
- 最常见的3/4级治疗中出现的不良事件为中性粒细胞减少。
核心结论
- 这些发现支持D-Rd在不适合移植的NDMM患者(入组MAIA研究)中的临床获益,无论衰弱状态如何。
研究设计与样本
- MAIA研究是一项3期试验,入组不适合移植的新诊断多发性骨髓瘤(NDMM)患者。
- 衰弱评估回顾性使用年龄、Charlson合并症指数和基线ECOG体能状态评分。
- 患者被分类为健康、中间、非衰弱(健康+中间)或衰弱。
- 随机分组:D-Rd组n=368,Rd组n=369;非衰弱患者396例(D-Rd组196例[53.3%],Rd组200例[54.2%]);衰弱患者341例(D-Rd组172例[46.7%],Rd组169例[45.8%])。
主要发现
- 中位随访36.4个月,非衰弱患者PFS长于衰弱患者,但D-Rd相比Rd的PFS获益在各亚组中均维持:非衰弱(中位PFS未达到 vs 41.7个月;HR 0.48;P<0.0001),衰弱(中位PFS未达到 vs 30.4个月;HR 0.62;P=0.003)。
- 在各亚组中,D-Rd组观察到更高的完全缓解或更好缓解率以及微小残留病(10-5)阴性率。
- 非衰弱和衰弱患者中最常见的3/4级治疗中出现的不良事件为中性粒细胞减少(非衰弱:D-Rd组45.4% vs Rd组37.2%;衰弱:D-Rd组57.7% vs Rd组33.1%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd). We present a subgroup analysis of MAIA by frailty status. Frailty assessment was performed retrospectively using age, Charlson comorbidity index, and baseline Eastern Cooperative Oncology Group performance status score. Patients were classified as fit, intermediate, non-frail (fit + intermediate), or frail. Of the randomized patients (D-Rd, n = 368; Rd, n = 369), 396 patients were non-frail (D-Rd, 196 [53.3%]; Rd, 200 [54.2%]) and 341 patients were frail (172 [46.7%]; 169 [45.8%]). After a 36.4-month median follow-up, non-frail patients had longer PFS than frail patients, but the PFS benefit of D-Rd versus Rd was maintained across subgroups: non-frail (median, not reached [NR] vs 41.7 months; hazard ratio [HR], 0.48; P < 0.0001) and frail (NR vs 30.4 months; HR, 0.62; P = 0.003). Improved rates of complete response or better and minimal residual disease (10-5) negativity were observed for D-Rd across subgroups. The most common grade 3/4 treatment-emergent adverse event in non-frail and frail patients was neutropenia (non-frail, 45.4% [D-Rd] and 37.2% [Rd]; frail, 57.7% and 33.1%). These findings support the clinical benefit of D-Rd in transplant-ineligible NDMM patients enrolled in MAIA, regardless of frailty status.
引用
- Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022. PMID: 34974527. doi:10.1038/s41375-021-01488-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。